These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 28161147)

  • 1. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    ; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
    JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
    Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
    Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
    Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
    Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
    Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
    Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
    Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.